A Study of LY3541105 in Healthy and Overweight Participants

Completed · Phase 1 · Has a placebo group

Conditions studied: Overweight, Healthy

In brief

The main purpose of this study is to evaluate the safety and tolerability of LY3541105 in healthy and overweight participants. Blood tests will be performed to check how much LY3541105 gets into the bloodstream and how long it takes the body to eliminate it. The study will also evaluate the effects of LY3541105 on body weight and assess safety and tolerability of LY3541105. This is a 3-part study and may last up to 15, 26 and 24 weeks for each participant and may include up to 7, 15 and 16 visits in parts A, B and C, respectively.

Key facts

Study ID
NCT05380323
Run by
Eli Lilly and Company
People needed
206
Starts
2022-05-10
Expected to finish
2024-08-27
Last updated by the study team
2025-06-27

Who can join

Age: 21 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.